Equity Overview
Price & Market Data
Price: $0.0239
Daily Change: -$0.0₃81 / 3.40%
Range: $0.0239 - $0.026
Market Cap: $1,912,570
Volume: 24,821
Performance Metrics
1 Week: -8.00%
1 Month: -35.39%
3 Months: -50.32%
6 Months: -59.47%
1 Year: -86.73%
YTD: -50.64%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.